VM 26 in advanced mycosis fungoides

Tumori. 1981 Oct 31;67(5):487-90. doi: 10.1177/030089168106700516.

Abstract

Five consecutive patients with progressive extracutaneous stage IV mycosis fungoides (MF) were treated with VM 25, 100 mg/m2 i.v., for at least 3 cycles. All patients had been extensively pretreated and in particular with vinca alkaloids. Two partial responses of 5 and 9+ months duration and 1 minimal response of 5 months duration were obtained. Transient myelosuppression was encountered in all patients. These preliminary results should encourage further exploration of VM 26, even in less advanced MF.

MeSH terms

  • Adult
  • Aged
  • Bone Marrow Diseases / drug therapy*
  • Female
  • Humans
  • Male
  • Mycosis Fungoides / drug therapy*
  • Podophyllotoxin / analogs & derivatives*
  • Skin Neoplasms / drug therapy*
  • Splenic Neoplasms / drug therapy*
  • Teniposide / therapeutic use*

Substances

  • Teniposide
  • Podophyllotoxin